Now showing items 1-20 of 45

Alteraciones en el sitio de administración reportadas por la aplicación intramuscular de medicamentos en Bogotá D. C. 2008-2017

Gil Barrera, Laura Carolina; Alvarez Ferrer, María Teresa (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2018Facultad de CienciasQuímica Farmacéutica, 2018)

En el presente artículo se describe los casos de alteraciones en el sitio de administración por la aplicación de medicamentos en Bogotá D.C. reportadas como evento adverso entre los años 2008 a 2017, es un estudio no ...
Caracterizacióbn de reacciones adversas con Trastuzumab reportadas en Bogotá D. C. 2008-2017

Garzón Fernández, Yeimy Lorena; Beltrán Angarita, Yuly Andrea (Facultad de CienciasQuímica Farmacéutica, 2018)

El cáncer de seno es el tipo de cáncer más frecuente en las mujeres de todo el mundo, con una incidencia que aumenta drásticamente con la edad. Según los informes, el cáncer de seno representó el 29% de todos los casos ...
Caracterización de efectos adversos a medicamentos asociados a trastornos hematológicos anemia, neutropenia y leucopenia reportados al Programa Distrital de Farmacovigilancia Bogotá D. C. 2012-2016

Cortés Torres, Eliana; Méndez Bernal, Yeimmy Viviana (Facultad de CienciasQuímica Farmacéutica, 2018)

Introducción. La detección, valoración, entendimiento y prevención de las reacciones adversas a medicamentos permiten mejorar el perfil de seguridad de los medicamentos comercializados en Colombia, es por ello que se realiza ...
Caracterización de eventos adversos a medicamentos asociados al Whoart alteraciones fetales reportados al programa distrital de farmacovigilancia durante el periodo 2012 a 2017

Montealegre Toloza, Gina Paola; Silva Sierra, Jessica Nataly (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

The use of drugs in the gestational state is of interest in Pharmacovigilance, because of the effects derived from consumption, which are sometimes unknown. In the present study, adverse events to medications related to ...
Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016)

Cruz Mateus, Angie Alexandra; Rodríguez Beltrán, Diego Alcibiades (Facultad de CienciasQuímica Farmacéutica, 2018)

Los corticosteroides son fármacos que poseen propiedades antiinflamatorias, antialérgicas e inmunosupresoras; fisiológicamente, se obtienen a partir del cortisol, el cual es una hormona que se produce en la corteza ...
Caracterización de eventos adversos e intoxicaciones reportadas por dipirona al programa distrital de farmacovigilancia Bogotá D.C 2008 - 2012

Torres Rodríguez, Yessika Paola; Ochoa León, Santiago (Facultad de CienciasQuímica Farmacéutica, 2013)

Se describieron los eventos adversos e intoxicaciones reportadas por el fármaco Dipirona al Programa Distrital de farmacovigilancia durante los años 2008 a 2012, realizando un estudio descriptivo de corte transversal y ...
Caracterización de eventos adversos y problemas relacionados con metoclopramida reportados al Programa Distrital de Farmacovigilancia en bogotá D. C. 2008-2017

Herreño Basabe, Jenny Paola (Facultad de CienciasQuímica Farmacéutica, 2018)

The drug under study of pharmacovigilance by the author is metoclopramide, Metoclopramide is a drug of the family of benzamides that has been used since its development in the 60s in diseases such as gastro ¬ diabetic ...
Caracterización de eventos adversos y problemas relacionados con Rivaroxaban reportadas al prorama Mundial de Farmacovigilacia 2006-2018

Espinosa Orozco, Lorena Isabel (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

Background: VTE represents an important health challenge that causes great impact to millions of people and the established anticoagulants used to prevent or treat the disease have significant limitations, including the ...
Caracterización de eventos adversos y problemas relacionados con toxina botulinica reportados al programa Distrital de Farmacovigilancia en Bogotá D. C. 2012-2017

Escobar Bedoya, Natalia María; Medina Gutiérrez, Heidy Viviana (Facultad de CienciasQuímica Farmacéutica, 2018)

Se realizó una revisión de todas las reacciones adversas reportadas en el programa de farmacovigilancia durante los años 2012-2017 sobre la toxina botulínica, entre estas surgieron 103 casos. Este es un medicamento producido ...
Caracterización de las reacciones adversas por Gabapentina reportados en Colombia 2008-2016

Dorado Mamian, Gleiny Viviana; Rodríguez Pedraza, Adriana Alejandra (Facultad de CienciasQuímica Farmacéutica, 2018)

Gabapentina (GBP) es un fármaco sintético análogo al ácido gamma amino butírico (GABA) aprobado inicialmente solo para uso en crisis parciales, pero también se mostró prometedor en el tratamiento de síndromes de dolor ...
Caracterización de los eventos adversos presentados por Bupivacaína reportados en la ciudad de Bogotá entre 2015-2018

Rodríguez Pedraza, Germán Camilo; Mejía Galvis, Jesús David (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

The AL can produce adverse reactions of varying degrees and different levels, despite the safety profile of local anesthetics, Bupivacaine (BVC) as a long-term local anesthetic is indicated in subarachnoid anesthesia to ...
Caracterización de reacciones adversas con naloxona Reportados en el programa mundial de farmacovigilancia de la organización mundial de salud (oms) 1974 -20181

González Jiménez, Kandy Lorena; Velandia Martín, Clara Lindely (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

The objective of this work is to characterize the adverse reactions with Naloxone reported in the World Pharmacovigilance Program of the World Health Organization (WHO) 1974-2018, the research is a cross-sectional descriptive ...
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018

Sánchez Triana, Jhoan Nicolás; Cadena Romero, Nicolás (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

One of the most important advances in modern medicine is the development of molecular biology with an emphasis on genetics, the advance has been so important that today enzymes can be isolated, such as agalsidase Alfa, ...
Caracterización de reportes de reacciones adversas psiquiátricas y problemas relacionados con el uso de Risperidona al Programa Distrital de Farmacovigilancia de Bogotá D. C. 2012-2016

Rosas Vega, Jaime Fabián; Villabón Usaquén, Edwin Camilo (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2020Facultad de CienciasQuímica Farmacéutica, 2020)

People's mental health can be affected by multiple factors, one of which is the use of medication, from the reports presented in Bogotá D.C. to the District Pharmacovigilance Program during the period 2012-2016, the drug ...
Estudio comparativo de reacciones adversas sospechosas con fármacos inhibidores de la bomba de protones reportados al programa Mundial de farmacovigilancia de 1984 a 2017

Vera Ortiz, Lizeth Yuliana; Peña Rodríguez, Omar Orlando (Facultad de CienciasQuímica Farmacéutica, 2018)

related to acidity and gastroesophageal reflux. Within this group of medicines we can find Omeprazole, Esomeprazole, Rabeprazole, Lansoprazole and Dexlansoprazole among others. These are generally characterized as very ...
Estudio de casos de alteraciones auditivas y vestibulares con fármacos reportados en Bogotá D. C. 2008-2018

Pérez Díaz, María Alejandra (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

The auditory and vestibular damages caused by the administration of ototoxic drugs are a threat that affects both children and adults, generating a deficient cognitive development and delay in speech, learning and language ...
Estudio de casos de eventos adversos y problemas relacionados con Denosumab reportados en Bogotá D. C. 2012-2017

Barbosa Amaya, Ana Milena; Saavedra Pinto, Lisett Carolina (Facultad de CienciasQuímica Farmacéutica, 2018)

The objective of this work is to characterize the adverse events of Denosumab that have been reported during the years 2012 to 2017 in the pharmacovigilance program of the district health secretary in Bogotá, Colombia. There ...
Estudio de casos de eventos adversos y problemas relacionados con Pegfilgastrim reportados en Bogotá D. C. (2012-2017)

Esguerra Gil, Erica Lilian (Facultad de CienciasQuímica Farmacéutica, 2018)

Currently the stimulating factors of human recombinant granulocyte colonies, is commercialized in Colombia under the name of Pegfilgrastim used for the treatment of Febrile Neutropenia associated with chemotherapy and ...
Estudio de casos de reacciones anafilácticas por administración de medicamentos reportados en la ciudad de Bogotá D. C. entre los años 2009-2018

Palacios Rodríguez, Edna Paola; Cucariano Camargo, Andrés Eduardo (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

In the present article the cases of anaphylactic reactions for administration of medications reported in the city of Bogotá DC, supplied by the district pharmacovigilance program, are reported, 173 cases were reported ...
Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable

Martínez Cardozo, Luz Adriana; Jiménez Guavita, Andersson Jair (Bogotá : Universidad de Ciencias Aplicadas y Ambientales, 2019Facultad de CienciasQuímica Farmacéutica, 2019)

The ductus arteriosus is a vascular structure that connects the proximal descending aorta with the main pulmonary artery near the origin of the pulmonary branch, (Ruiz, D; et al. 2008) and that results in a pulmonary ...

Envíos recientes

Alteraciones en el sitio de administración reportadas por la aplicación intramuscular de medicamentos en Bogotá D. C. 2008-2017
...
Gil Barrera, Laura Carolina | 2018

En el presente artículo se describe los casos de alteraciones en el sitio de administración por la aplicación de medicamentos en Bogotá D.C. reportadas como evento adverso entre los años 2008 a 2017, es un estudio no experimental, descriptivo y de corte transversal; inicialmente se cuenta con 771 casos donde se evidencia alteraciones en el sitio de administración, solo se tomaron intramusculares para el estudio, descartando los demás casos, teniendo así un total de 74 reportes de alteraciones en el sitio de administración por vía intramuscular. En conclusión, las mujeres presentan más reacciones adveras en comparación a los hombres, las edades más críticas en los cuales se presentan reacciones adversas y problemas relacionados con medicamento son de 0-4. Se evidencio que los fármacos con más reportes para PRM son diclofenaco y vacunas (tétano y DPT), y como RAM diclofenaco y penicilina benzatinica.

LEER
Caracterizacióbn de reacciones adversas con Trastuzumab reportadas en Bogotá D. C. 2008-2017
...
Garzón Fernández, Yeimy Lorena | 2018

El cáncer de seno es el tipo de cáncer más frecuente en las mujeres de todo el mundo, con una incidencia que aumenta drásticamente con la edad. Según los informes, el cáncer de seno representó el 29% de todos los casos nuevos de cáncer y el 14% de todas las muertes relacionadas con el cáncer entre las mujeres de todo el mundo hasta el 2012. En Colombia, la incidencia de esta enfermedad presentó un incremento en el número de casos diagnosticados de 2010 a 2014. Por otra parte, El cáncer gástrico es la segunda causa de mortalidad por cáncer en el planeta y la quinta incidencia anual por tumores malignos. En Colombia, el cáncer gástrico se encuentra dentro de los diez 10 neoplasmas con mayor prevalencia en ambos sexos. Siendo la principal causa de muerte en hombres durante el periodo 2010-2014. El cáncer de seno, al igual que el cáncer de estómago, sobreexpresan el receptor 2 del Factor de Crecimiento Epidérmico Humano (HER-2), a los cuales se les denomina como cáncer HER-2 positivo (HER-2+). Trastuzumab es un medicamento de anticuerpos monoclonales usado para tratar el cáncer de seno y estómago HER-2+, cuya eficacia ha sido comprobada en múltiples estudios; de igual forma, varias guías de práctica clínica soportan su uso. Basados en esto, el presente trabajo busca caracterizar las reacciones adversas a medicamentos con trastuzumab reportadas en la ciudad de Bogotá D.C. durante los años 2008-2017

LEER
Caracterización de efectos adversos a medicamentos asociados a trastornos hematológicos anemia, neutropenia y leucopenia reportados al Programa Distrital de Farmacovigilancia Bogotá D. C. 2012-2016
...
Cortés Torres, Eliana | 2018

Introducción. La detección, valoración, entendimiento y prevención de las reacciones adversas a medicamentos permiten mejorar el perfil de seguridad de los medicamentos comercializados en Colombia, es por ello que se realiza el presente estudio con reportes del programa distrital de farmacovigilancia. Objetivo. Analizar los casos reportados al programa distrital de farmacovigilancia en Bogotá DC durante el periodo del 2012 al 2016, identificando la anemia, neutropenia y leucopenia como reacción adversa a medicamentos. Métodos. Se realizó un análisis de cada reporte, y un análisis descriptivo que permitió identificar la frecuencia de los medicamentos asociados a estos trastornos hemolíticos (Anemia, neutropenia y leucopenia) como también la causalidad, y la severidad de estos eventos. Esta información se correlaciono con la literatura científica obtenida a través de una revisión bibliográfica en bases de datos como PubMed y EBSCO con los términos DeCs: efectos de los medicamentos, leucopenia, neutropenia, anemia y MeSH: adverse drug reaction, anemia, neutropenia, leukopenia. Resultados. Se analizaron 225 reportes enviados al Programa Distrital de Farmacovigilancia (PDFV) en la ciudad de Bogotá D.C entre los años 2012 a 2016 todos relacionados con los desórdenes hematológicos: Anemia, Neutropenia y Leucopenia. El mayor número de reportes 80 (35%) casos se presentaron en el 2016, más en mujeres que en hombres. Los reportes relacionados con anemia se presentaron más en hombres que en mujeres, mientras que leucopenia y neutropenia más en mujeres. La mayoría de los eventos Anemia, Neutropenia y Leucopenia se presentaron en adultos entre 27 y 59 años. Dentro de los principales medicamentos asociados en Anemia se encuentran Lamivudina+Zidovudina (33 reportes), Palivizumab (24 reportes) y Adalimumab (9 reportes). Con el evento neutropenia los principales medicamentos reportados son Azatioprina (3 reportes), Doxorubicina (3 reportes), Vancomicina (3 reportes).La leucopenia se presenta principalmente con los medicamentos Tocilizumab (8 reportes), Piperacilina (6 reportes) y Metotrexato (6 reportes). La causalidad en los tres eventos principalmente se encuentra en la categoría de posible y probable, bajo el algoritmo de naranjo. En el estudio no se encontró literatura relacionada con leucopenia y uso de Metotrexato, Neutropenia y uso de Azatioprina o Doxorubicina, ni tampoco de Anemia y Palivizumab. Conclusiones. Este estudio se desarrolla en la etapa de pos comercialización, complementa el perfil de seguridad de los medicamentos e incluye otros medicamentos asociados a trastornos hematológicos, esta información es de utilidad para el profesional de la salud que usa estos medicamentos en la práctica habitual y puede dar recomendaciones de seguridad y seguimiento con el uso de la terapia farmacológica.

LEER
Caracterización de eventos adversos a medicamentos asociados al Whoart alteraciones fetales reportados al programa distrital de farmacovigilancia durante el periodo 2012 a 2017
...
Montealegre Toloza, Gina Paola | 2019

The use of drugs in the gestational state is of interest in Pharmacovigilance, because of the effects derived from consumption, which are sometimes unknown. In the present study, adverse events to medications related to the WHOART Fetal Alterations, occurred and reported in the city of Bogotá, were analyzed. An analysis was made of the reports between 2012 and 2017 that were notified to the District Pharmacovigilance Program related to the WHOART fetal alterations, classifying them into Adverse Drug Reactions (RAM). The WHO algorithm was used to classify the RAM; The causality of the RAM was evaluated using the WHO algorithm. In summary, 4 abortion notifications, 2 congenital heart diseases, 1 case of polydactyly and 1 of bradycardia were presented. All serious serious reports. According to type of RAM, the majority of reports correspond to type A with 7 cases, type D a case. According to the WHO algorithm, 4 of the cases were classified as Probable, 1 cases as Unclassifiable due to the little information reported by the notifier, 2 possible case, 1 unlikely case. According to the reports analyzed for the WHOART Fetal disorders it was found that, of the 8 cases, 2 were registered by antiepileptics such as Valproic Acid and Levetiracetam. The presence of congenital heart disease in the report of the newborn is probably due to the Levetiracetam to which the mother was exposed, a probable mechanism of the teratogenic action of antiepileptics, is the production of heart rhythm disorders by direct action of drugs on the fetal heart Another case of adverse reaction in newborns occurs in childbirth when peridural anesthesia with bupivacaine is administered in a pregnant mother, developing bradycardia in the newborn. From the report in which abortion was recorded due to the consumption of the antidepressant Bupropion, the literature mentions that the use of this medication during the first trimester has been associated with fetal heart malformations in 1.3% and abortions in 15.4%. medications associated with congenital heart disease presented in the report, are Hydralazine, which has been the most commonly used treatment in severe hypertensive crisis and pre-eclampsia, with no teratogenic effects detected. Information from the present study shows that immunosuppressive therapies are associated with spontaneous abortion, such as fingolimod and natalizumab. According to a case study conducted with Fingolimod in pregnant patients, it is reported that spontaneous abortion occurs in 15% to 20% of known pregnancies, and the main birth defects occur in 4% to 8% of pregnancies. The same happens with natalizumab, which is not recommended for use during breastfeeding or pregnancy. Finally, reported abortion is reported, due to the administration of Tocilizumab in combination with Methotrexate, according to a clinical study it is confirmed that Methotrexate is a known and abortive teratogen.

LEER
Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016)
...
Cruz Mateus, Angie Alexandra | 2018

Los corticosteroides son fármacos que poseen propiedades antiinflamatorias, antialérgicas e inmunosupresoras; fisiológicamente, se obtienen a partir del cortisol, el cual es una hormona que se produce en la corteza suprarrenal. Los derivados sintéticos están indicados en el tratamiento de enfermedades reumáticas, dermatológicas, respiratorias, renales, entre otras. Teniendo en cuenta que el número de medicamentos originados de la molécula del cortisol es amplio, asi como las vías de administración por las que se pueden utilizar, se realizó un estudio descriptivo de carácter transversal, siendo éste a su vez, retrospectivo; proporcionándose una visión de los eventos adversos generados específicamente por corticosteroides como son, Prednisona, Prednisolona, Hidrocortisona, Metilprednisolona, Dexametasona, Betametasona, Mometasona, Fluticasona, Beclometasona y Clobetasol. Basados en casos reportados al Programa Nacional de Farmacovigilancia, entre el periodo de 2005 a 2016, en donde se encontraron 801 casos reportados, de los cuales solo se tuvieron en cuenta 551, siendo excluidos 250 casos, ya que presentaron duplicidad, es decir, reportes que en la descripción del evento, fecha de inicio y datos de paciente son iguales, y a su vez algunos carecieron de información para llevar a cabo el análisis. Fueron analizados por año, género, grupo etario, tipo de medicamento, departamento; clasificados según el tipo de seriedad y causalidad descrita por la OMS y Uppsala (UMC), y según terminología de la OMS (WHOART). Se encontraron 551 casos en donde la mayoría de eventos adversos fueron presentados por pacientes de género femenino; la edad donde se evidenció mayor cantidad de eventos adversos fue entre los 50 y 64 años; se observó mayor número de eventos adversos en el año 2016 (50,1%); la Prednisolona fue el medicamento que presentó mayor cantidad de eventos adversos con 244 casos (44%); Bogotá fue el lugar que más aportó al total de eventos adversos con 186 notificaciones (33.8%); con respecto a seriedad, la variable predominante fue la notificada como “No serio”, para lo cual se presentó un total de 336 casos reportados, siendo equivalentes al 61%; la causalidad para la mayoría de los casos fue “posible” con 391 reportes (71%).

LEER
Caracterización de eventos adversos e intoxicaciones reportadas por dipirona al programa distrital de farmacovigilancia Bogotá D.C 2008 - 2012
...
Torres Rodríguez, Yessika Paola | 2013

Se describieron los eventos adversos e intoxicaciones reportadas por el fármaco Dipirona al Programa Distrital de farmacovigilancia durante los años 2008 a 2012, realizando un estudio descriptivo de corte transversal y Retrospectivo, describiendo variables específicas ya determinadas en el formato de la Secretaria Distrital de Salud y el formato de notificación de intoxicaciones Sivigila. Se analizaron 297 casos aportados por el programa de farmacovigilancia, denotando que la mayor población afectada por los eventos adversos se encuentra en un rango de edad de 25 a 29 años con mayor presencia del sexo femenino (56,2 %). En general los casos fueron clasificados con una gravedad moderada (51,5 %) y de causalidad probable (52,7 %); la reacción más recurrente fue de tipo rash (15,9 %) con mayor incidencia de la Vía Intravenosa (68,3 %). Y por último en el análisis de los 10 casos aportados por los reportes de intoxicaciones del Sivigila resalta que la población principalmente afectada se encuentra en un rango de edades de 20 a 24 años siendo el sexo femenino el mayor incidente con un 80,0 % con un 60,0 % de exposición suicida. Demostrando así que el uso de la Dipirona de forma crónica representa un riesgo potencial para la ocurrencia de los diferentes eventos adversos, por lo cual estos pacientes deben contar con vigilancia constante, basados en los resultados que demuestren los análisis médicos de rutina tanto clínicos como de laboratorio apoyado también en la educación de los pacientes para que generen recordación sobre sus antecedentes médicos.

LEER
Caracterización de eventos adversos y problemas relacionados con metoclopramida reportados al Programa Distrital de Farmacovigilancia en bogotá D. C. 2008-2017
...
Herreño Basabe, Jenny Paola | 2018

The drug under study of pharmacovigilance by the author is metoclopramide, Metoclopramide is a drug of the family of benzamides that has been used since its development in the 60s in diseases such as gastro ¬ diabetic paresis, gastroesophageal reflux, dyspepsia associated with disorders of the mo ¬ gastrointestinal sensitivity, prevention and management of nausea and vomiting of patients in palliative care, chemotherapy or postsurgical, among others. This study is proposed because in clinical practice it is evident that this drug is used in some cases indiscriminately, without taking into account the pathology to be treated, its severity, duration of treatment, its metabolization and / or adequate characteristics of the drug, since this drug is prescribed in complex pathologies (gastroenteritis, migraines, chemotherapy treatments) and that frequently require chronic use, as is already known, the action of a drug can be altered, by the action of food, by the same disease , by unique characteristics of the patient, by interaction with other medicines or by the prolonged use of them, producing adverse effects, some with more incidence than others and that can even end up causing collateral effects. For the development of this project, a cross-sectional descriptive study of the data of adverse events to metoclopramide reported to the district health program of Bogotá was carried out. The described variables were related to factors of person, time, place and those of the events adverse, for the period under study from 2008 to September 29, 2017. The results obtained from the District Pharmacovigilance program in Bogotá were grouped taking into account variables such as age, gender, ADR, causality, severity and severity, PRM, therapeutic failure among others. The pharmacovigilance reports related to the drug metoclopramide, represented 297 cases in which the majority of adverse reactions were caused to female patients between the age range 0-12 months, and 20-34 years years, much of the adverse reactions related symptoms such as headache, Rash, extrapyramidalism, drowsiness, dizziness, erythema, pain, among others, and a small portion due to more severe reactions such as renal failure and tardive dyskinesia, central nervous system disorders and symptoms related to the literature, and that occur during therapy or even after the treatment is finished. Likewise, it was found that 13.80% of the reports corresponded to problems related to medications, many of these cases were due to errors at the time of dispensing, problematic of the places destined to the delivery of the medication when confusing the prescribed dose, human errors that they should be minimized to the maximum to ensure that the patient receives the appropriate medication in the proper dose. It is considered highly significant to initiate processes aimed at raising awareness among patients, as well as the medical team taking into account that these should be responsible for encouraging and motivating the patient, as well as being receptive to the information provided by patients within the treatment. verbal or written for the purpose of obtaining timely information about the adverse events that could occur due to the consumption of these medications. To assist with the training and awareness of the pharmacological monitoring process, it will be attached as Annex 1. An educational poster, with information concerning the possible adverse events and symptoms that each patient could present when using the medication in order to optimize the use of the group of medicines and provide the correct and necessary care to be able to watch over and preserve the patient's health.

LEER
Caracterización de eventos adversos y problemas relacionados con Rivaroxaban reportadas al prorama Mundial de Farmacovigilacia 2006-2018
...
Espinosa Orozco, Lorena Isabel | 2019

Background: VTE represents an important health challenge that causes great impact to millions of people and the established anticoagulants used to prevent or treat the disease have significant limitations, including the need for parenteral administration, regular monitoring and lack of predictable response. Rivaroxaban was approved by the European authorities in 2008 for the prevention of venous thromboembolism (VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism) after elective hip or knee replacement. One of the main reasons for the importance of the discovery of this molecule called Rivaroxaban is its significant contribution to the treatment and prevention of venous thromboembolism (VTE). VTE represents an important health challenge that causes great impact to millions of people and the established anticoagulants used to prevent or treat the disease have significant limitations, including the need for parenteral administration, regular monitoring and lack of predictable response. The aim of the present study is to characterize the adverse events with Rivaroxaban reported to the World Pharmacovigilance Program in the period 2006-2018. Methods: Retrospective descriptive observational study, cases reported by the Uppsala Monitoring Center database worldwide. Results: During the period January 1st 2006 to November 20th 2018 was found 224.320 adverse events mostly, about (39%) related with hemhorrages, Mainly gastrointestinal bleeding is the most augmented adverse reaction for Rivaroxaban with no distinction of gender. Age is a risk factor for population >75 years old. América is the continent with more adverse reactions reported, this because of the active pharmacovigilance plans that this continent has. Some of the problem related with rivaroxaban being an anticoagulant are related with over-dosification or Quality problems like label, package where rivaroxaban is contained. Conclusions: Adverse events are most likely gastrointestinal disorders. The more are gastrointestinal bleeding, event which is a preoccupation for gastroenterologists. The pharmaceutical attention is a network whose strategy is being aware of the complications that the patient has when is prescribed with new anticoagulants with rivaroxaban. It has been made a proposal communicative piece in order to inform possible risks related with anticoagulant therapy.

LEER
Caracterización de eventos adversos y problemas relacionados con toxina botulinica reportados al programa Distrital de Farmacovigilancia en Bogotá D. C. 2012-2017
...
Escobar Bedoya, Natalia María | 2018

Se realizó una revisión de todas las reacciones adversas reportadas en el programa de farmacovigilancia durante los años 2012-2017 sobre la toxina botulínica, entre estas surgieron 103 casos. Este es un medicamento producido por la bacteria anaeróbica Clostridium Botulinum. La toxina tipo A fue la primera que se aisló, purifico y es la que más frecuentemente se usa en la clínica por varias razones: disponibilidad, aspecto inmunológico, seguridad y eficacia. Se utiliza para diferentes enfermedades, como parálisis facial, estrabismo, espasticidad, incluso para tratamientos estéticos etc. Se analizaron los respectivos casos en donde encontramos que se descartaron 22 por falta de información lo que conlleva a realizar el procedimiento para 81. Se evidencia que en el año 2016 se presenta una elevación de los casos reportados en lo que se presume que este incremento puede estar relacionado tanto con el aumento de pacientes medicados con toxina botulínica, así como un incremento en la recolección de datos observando una constante, idónea y confiable de información importante y fundamental sobre algunas condiciones de salud de la población. También se observa que de los 81 casos 75 fueron considerados como RAM y 6 como PRM, de esas RAM las de mayor incidencia fueron las de fallo terapéutico lo cual se clasificaron con el algoritmo de cimun.

LEER
Caracterización de las reacciones adversas por Gabapentina reportados en Colombia 2008-2016
...
Dorado Mamian, Gleiny Viviana | 2018

Gabapentina (GBP) es un fármaco sintético análogo al ácido gamma amino butírico (GABA) aprobado inicialmente solo para uso en crisis parciales, pero también se mostró prometedor en el tratamiento de síndromes de dolor crónico, especialmente neuropático. En el presente estudio se realizó un estudio descriptivo retrospectivo de 68 casos de eventos adversos con gabapentina reportados al Instituto Nacional de Vigilancia de Medicamentos y Alimentos Invima durante los años 2008 al 2016. Se usaron las variables seriedad, causalidad, descriptor, grupo etario, sexo y ciudad del reporte. Se identificaron (90%,61 reportes) de reacciones adversas y (10%,7 errores) de medicación con Gabapentina. Los casos predominan en el sexo femenino; y pacientes entre los 71 a 80 años (31%, 21 casos) y de 51 a 60 años (29%, 20 casos). Los descriptores más frecuentemente asociados fueron diarrea, mareo, prurito, debilidad generalizada y somnolencia. La causalidad fue clasificada principalmente como probable. Los reportes predominaron en la ciudad de Bogotá (60%, 41 casos) y Medellín (13%, 9 casos). Los casos serios alcanzaron el (34%,23 casos) con un solo caso con condición final muerte. Se concluye que las principales reacciones adversas más frecuentes fueron relacionadas con la depresión del sistema nervioso central y periférico y alteraciones en la piel.

LEER
Caracterización de los eventos adversos presentados por Bupivacaína reportados en la ciudad de Bogotá entre 2015-2018
...
Rodríguez Pedraza, Germán Camilo | 2019

The AL can produce adverse reactions of varying degrees and different levels, despite the safety profile of local anesthetics, Bupivacaine (BVC) as a long-term local anesthetic is indicated in subarachnoid anesthesia to perform Interventions in lower extremities, perineum, lower abdomen; Normal vaginal delivery and Caesarean section and reconstructive surgery of the lower extremities. However, multiple cases reported and different clinical studies have indicated that the bupivacaine is indicated in anesthesia of processes dental by infiltration or blocking truncal. Its main drawback is its potential cardiotoxicity. This article is elaborate in order to make known the information obtained through a study of adverse events reported in the city of Bogotá between the years 2015-2018, resulting in the bupivacaine generates more RAM type therapeutic failure and are presented More cases in women than in men according to the great use that is given in procedures directed to the female gender, but without representing a high index of risk related to the use of this medicine

LEER
Caracterización de reacciones adversas con naloxona Reportados en el programa mundial de farmacovigilancia de la organización mundial de salud (oms) 1974 -20181
...
González Jiménez, Kandy Lorena | 2019

The objective of this work is to characterize the adverse reactions with Naloxone reported in the World Pharmacovigilance Program of the World Health Organization (WHO) 1974-2018, the research is a cross-sectional descriptive research design was carried out with a systematized review and was not manipulated the independent variables, it is said that it is a descriptive analysis since the frequency and the values that manifested the different variables were analyzed, providing a view of the reports of RA by the drug Naloxone to the global program of pharmacovigilance of the WHO between the years 1974-2018. During the period from 1974 to 2018, the VigiAccess Global Pharmacovigilance Program received a total of 1,684 reports associated with the use of Naloxone. These reports were characterized and analyzed in their entirety according to the year of the report, distribution by continents, gender, age group, system / organ classification and descriptors. The year in which there were more reports of adverse reactions was 2017, where there were 315 cases reported. The continent that presented the highest percentage of reports of adverse reactions was Asia with 46%. The gender with the highest representation was the male with 49% of R.A reported. The age group with the highest prevalence of R.A was in patients between the range of 45-68 years (29%). The most prevalent descriptors were: nausea, vomiting, dizziness, dyspnea, rash and chest pain, in conclusion the most common adverse reactions such as nausea, vomiting, dizziness, dyspnea, rash and chest pain, between the range of 45- 64 years and the male gender have more cases of adverse reactions. Asia is the continent that presents the highest number of reports compared to other continents

LEER
Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018
...
Sánchez Triana, Jhoan Nicolás | 2019

One of the most important advances in modern medicine is the development of molecular biology with an emphasis on genetics, the advance has been so important that today enzymes can be isolated, such as agalsidase Alfa, agalsidase Beta, Alglucosidase, Asparaginase, Streptokinase, Idursulfase, Imiglucerase, Laronidase and Tenecteplase. These drugs are used for enzymatic, antineoplastic and thrombolytic replacement therapy, for which it is necessary to conduct a pharmacovigilance study, in which the different adverse reactions to them were analyzed. The information collected were 231 cases, in which they presented 4 PRM and 227 RAM, the highest incidence occurs in men, where a significant number of cases are in an age range between 0 to 5 years old. In most cases, reactions associated with an immune response were determined. 7

LEER
Caracterización de reportes de reacciones adversas psiquiátricas y problemas relacionados con el uso de Risperidona al Programa Distrital de Farmacovigilancia de Bogotá D. C. 2012-2016
...
Rosas Vega, Jaime Fabián | 2020

People's mental health can be affected by multiple factors, one of which is the use of medication, from the reports presented in Bogotá D.C. to the District Pharmacovigilance Program during the period 2012-2016, the drug with the highest incidence is Risperidone, the reports were analyzed by standardizing the different prescription reason to three spectrums, schizophrenia, bipolar affective disorder and autism, with the criteria established in the DSM5, the DSM5 symptom intensity rating tool, and supported by studies linking anxiety to the schizophrenic episode, cases were reclassified as therapeutic failure because they fit into a symptom reactivation, these were evaluated with CIMUN algorithm. The main findings show that the failures occurred in 96 cases and a part of them during the first year of treatment. In the cases wich was concomitant consumption of alcohol or psychoactives there was reactivation of symptoms. The most frequent reason for presciption corresponds to the spectrum of schizophrenia, the specificier of seriousness that prevailed was Serious - severe, this due to the high rate of hospitalization. The masculine gender is the most commonly reported, and the predominant age group is 27-59 years old. More specific studies are suggested to establish the effectiveness of the drug in the early stage of the disorders in which it´s use is indicated and to identify factors external to the drug that may cause reactivation of symptoms

LEER
Estudio comparativo de reacciones adversas sospechosas con fármacos inhibidores de la bomba de protones reportados al programa Mundial de farmacovigilancia de 1984 a 2017
...
Vera Ortiz, Lizeth Yuliana | 2018

related to acidity and gastroesophageal reflux. Within this group of medicines we can find Omeprazole, Esomeprazole, Rabeprazole, Lansoprazole and Dexlansoprazole among others. These are generally characterized as very safe drugs that have a high efficacy and safety, however the increase in their consumption and prescription in recent years has caused the appearance of various disorders present both in their short-term and long-term use, being the most worrisome the disorders presented by consuming them in long periods of time. At the same time and based on different problems that have arisen worldwide with the consumption of medicines, we have the birth of different pharmacovigilance programs, being the pioneer the international pharmacovigilance program of the WHO (World Health Organization), the which, with the help of other entities such as the UMC (Uppsala Monitoring Center), have helped to considerably improve the health of people with their programs for the reporting and control of adverse drug events and thanks to this they have improved more and more, creating better programs and providing information for the whole community in general. Among these programs we have VigiBase and VigiAccess, databases that support each other, being the VigiAccess the one that takes the information that is reported in the VigiBase, and also having the characteristic of stratifying the notifications made by sex, age, geographical location, year of report and classify the reactions according to their symptomatology. With the help of this database it is that in this study the different analyzes of each of the PPIs mentioned above are carried out and that the purpose is to compare the adverse reactions reported in these databases for each of the aforementioned drugs, evaluating the variables that can be obtained from this interface and in this way establish which factors influence or have influenced over the years that may have increased or decreased the number of adverse reactions reported, addressing issues such as self-medication, self-prescription, safety of the different generations of PPIs, a poor diagnosis, among others. According to the results obtained and clearly evidencing a problem of duplication of information within the VigiAccess interface for some items, we can establish that the drugs that report the most adverse reactions are Omeprazole and Esomeprazole, as well as the one that presents the least is Dexlansoprazole, in turn in terms of sex reports, there is a clear advantage of male versus female having the latter a greater number of reports. In terms of geographical location, we observed a greater number of reports for the American continent and the lowest for the continent of Africa, by age, people between 44 and 65 are the ones that have presented the most reactions and per year of reports, each PPI has a year in which more events have been presented, however Esomeprazole is the one that presents major peaks in many years different from the other PPIs From the above it was concluded that Esomeprazole was the drug with the most reports presented during the years from 1984 to 2017 followed by Omeprazole, something curious considering that Omeprazole is the longest PPI on the market, however to take into account that there are data duplication errors that could affect the result. In turn, it was possible to determine, based on the reported events, which PPIs have higher and lower reports according to the year, geographical location, sex and age, which allows determining which population is the most vulnerable, also if it has been improved. the safety of PPIs with the development of different generations, or if factors such as location or gender influence to present more or less adverse reactions, also taking into account pharmacovigilance programs in different parts of the world. Finally, and with the help of the information obtained, this scientific article was developed, and a brochure was designed with clear and concrete information about the care and proper use when consuming a PPI, making known its main functions as well as complications and This way inform about the importance of reporting the eventualities that may occur when consuming these medications.

LEER
Estudio de casos de alteraciones auditivas y vestibulares con fármacos reportados en Bogotá D. C. 2008-2018
...
Pérez Díaz, María Alejandra | 2019

The auditory and vestibular damages caused by the administration of ototoxic drugs are a threat that affects both children and adults, generating a deficient cognitive development and delay in speech, learning and language in the case of children. Many of the ototoxic drugs play an important role in the treatment of serious or life-threatening diseases and offer important therapeutic effects, so that the risk of ototoxicity can be considered minor. The incidence of ototoxicity cases may increase, because some of these drugs are highly effective and low cost, so they are easily accessible without having any adequate control. This is why the present research work seeks to characterize the adverse reactions of drugs reported in Bogotá in the period 2008 to 2018. For this, a type of non-experimental-descriptive study with a quantitative cross-sectional approach was used since it was based on in reports of auditory and vestibular alterations which were reported in the District Pharmacovigilance Program in the city of Bogotá. Where a total of 88 cases were obtained, in which it was possible to demonstrate that the pharmacological groups with the highest prevalence are (Monoclonal Antibodies, aminoglycosides, antineoplastic, being the most frequent adverse reaction Otalgia, followed by Tinnitus.) It is concluded that the seriousness of the cases reported is of the Non-serious-moderate type since the patient's life was not compromised, however, the importance of the therapeutic treatment existed.

LEER
Estudio de casos de eventos adversos y problemas relacionados con Denosumab reportados en Bogotá D. C. 2012-2017
...
Barbosa Amaya, Ana Milena | 2018

The objective of this work is to characterize the adverse events of Denosumab that have been reported during the years 2012 to 2017 in the pharmacovigilance program of the district health secretary in Bogotá, Colombia. There is a varied group of pharmaceutical alternatives approved to treat osteoporosis, these contemplate medicines for prevention and treatment. Currently in Colombia are approved: Bisphosphonates (Alendronate, Etidronate, Risedronate), Calcium as a supplement, alone or in combination with vitamin D, selective modulator of estrogen receptors (Raloxifene) and a parathyroid hormone analogue (Teriparatide), among others. These drugs reduce the risk of fracture by different mechanisms of action in patients who have suffered fractures due to fragility and / or diagnosis of osteoporosis. Pharmacotherapy can also reduce the risk of fracture in patients with low bone mass, without previous fractures. Currently there is great concern about its safety with long-term use, for this reason several associations worldwide such as: the American Society for Bone and Mineral Research, the National Osteoporosis of the United Kingdom Group of Guides and the European Menopause and Andropause Society have published about the balance risk benefit and the use of drugs such as bisphosphonates. The drug of interest in this review is denosumab. Denosumab is a human monoclonal IgG2 antibody, it has high affinity and specificity for the human receptor activator of nuclear factor kappa-B ligand (RANKL), the main regulator of osteoclastic bone resorption. Denosumab binds to RANKL, which prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. This acts to inhibit the formation, function and survival of osteoclasts, thus decreasing bone resorption. Denosumab is an effective and safe treatment option for osteoporosis, with current data of up to 8 years of continuous use that show a continuous improvement in bone density with a sustained reduction in fracture risk. There is a greater theoretical risk of infection with the inhibition of RANKL. Future considerations include the safety of prolonged treatment beyond 8 years, and the risk of efficacy / fracture after discontinuation or non-adherence, given the characteristic pharmacodynamic profile of denosumab. Denosumab is the first and so far the only RANKL inhibitor approved for the treatment of osteoporosis. It is extremely effective in reducing bone turnover and has reversible effects on interruption. Since its approval, it has demonstrated sustained efficacy in increasing BMD and reducing the risk of fractures, with extension data now through 8 years of use. Although safety has been a concern for this agent given its novel mechanism, current post-marketing data appear favorable in this regard, showing good tolerability and safety compared to placebo and bisphosphonates. The initial approval of the United States FDA for denosumab was in June 2010 for the indication of the treatment of osteoporosis in postmenopausal women at high risk of fracture. In September 2011, the FDA granted an additional indication for treatment to increase bone mass in men at high risk of fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and to increase bone mass in women with high fracture risk receiving therapy for breast cancer. In September 2012, denosumab was approved to increase bone mass in men with osteoporosis with a high risk of fracture. A dose of 60 mg is administered every 6 months subcutaneously. Currently the drug is marketed in Colombia under its two registered trademarks: PROLIA and XGEVA, after subcutaneous administration it is evident that the bioavailability of PROLIA is 78% while that of XGEVIA is 62%. Different adverse reactions have been detected after drug consumption, being the most important: urinary tract infection, respiratory infection, cataracts, joint pain and osteonecrosis processes. In Colombia, there is a national pharmacovigilance program led by INVIMA (national food and drug surveillance institute) whose objective is to monitor medicines after they are being marketed to determine the safety of them, in turn. It has a district pharmacovigilance program from which 55 reports of adverse reactions produced by Denosumab were obtained in the period from 2012 to 2017. This is an observational descriptive study of a series of cross-sectional cases. The Case Reports methodology is used. The age and sex description is made. The seriousness, the causality and the descriptors of the World Health Organization are classified. Alphabetical classification is used according to the mechanism of action of the drug. Results: A total of 55 reports were analyzed, where there are 9 medication errors and 46 adverse reactions, of these the most frequent were alterations in the skin and general. 15% of cases (n = 8) are serious events, two related to death classified as unlikely. Causality in most cases is possible with 45% (n = 25). The age of the patients ranges from 50 to 88 years, the most frequent sex is female with 89% (n = 49) It is concluded that 84% of the cases analyzed, n = 46 correspond to ADR derived from the administration of denosumab, it is important to mention that information about the safety of the drug is scarce since it has been on the market for less than 10 years. which makes this characterization of great importance in the quantification of new adverse reactions.

LEER
Estudio de casos de eventos adversos y problemas relacionados con Pegfilgastrim reportados en Bogotá D. C. (2012-2017)
...
Esguerra Gil, Erica Lilian | 2018

Currently the stimulating factors of human recombinant granulocyte colonies, is commercialized in Colombia under the name of Pegfilgrastim used for the treatment of Febrile Neutropenia associated with chemotherapy and Severe Neutropenia since 2005. With the identification of adverse events and problems related to the medicine is to observe the problems and risks that are associated with the use of the drug, in order to identify the problem and establish possible solutions ensuring safety of them, establishing variables and analyzing the cases reported by the pharmacovigilance program of the secretary of health during the period of 2012 - 2017. For this a non-experimental, descriptive statistical analysis is carried out, taking the reports of the reports of suspected adverse reactions with Pegfilgrastim between the years 2012 - 2017. As a result, a total of 18 cases presenting greater percentage the suspicions of adverse reactions with 94%, finding bone pain, dizziness and generalized weakness as the manifestations mostly reported; as for the severity with greater occurrence, the moderate non-seriousness is evidenced with a total of 9 cases reported; the causality of the events was with an equal number of reports probable and possible causality with 47% respectively; Regarding the problems related to the medication, 6% of the cases relate directly to a negative result associated with the medication with an untreated health problem.

LEER
Estudio de casos de reacciones anafilácticas por administración de medicamentos reportados en la ciudad de Bogotá D. C. entre los años 2009-2018
...
Palacios Rodríguez, Edna Paola | 2019

In the present article the cases of anaphylactic reactions for administration of medications reported in the city of Bogotá DC, supplied by the district pharmacovigilance program, are reported, 173 cases were reported between the years 2009-2018, of which two cases had as alteration general death. In conclusion, women presented more reports of anaphylactic reactions due to the use of drug compared to men, the ages with the most reports being pediatric patients under 4 years (10%), followed by reports of ages between 35-39 years (8%) and finally the group with the highest number of reports were patients aged 60-64 years (15%). It was evidenced that the pharmacological groups that most report of anaphylactic reactions are the analgesics followed by the betalactamic antibiotics. METHODS: A descriptive, retrospective study of cases reported in the District Pharmacovigilance Program of the District Secretary of Health of the city of Bogotá. RESULTS: In accordance with the cases of anaphylaxis reported by the District Pharmacovigilance Program, in the period between 2009 and 2018 in the city of Bogotá, the relevant data for this study were analyzed, with a total of 173 reports that , according to the inclusion criteria, they allowed us to evaluate different variables to identify the causes that generate anaphylaxis from the use of medications in the population, often we find the inconvenience that these reports are made by different people, each one provides a description typical of the same event they study, for this reason the descriptions were unified so that they are categorized in the same way and thus perform a correct analysis of the reports, in our study 541 Whoart descriptors were categorized in which it stood out with a total of 233 cases (43.1%) general alterations and subclassification the anaphylactic shock reports No 68 cases equivalent to 13%. CONCLUSIONS: The characterization and analysis of the reported cases of anaphylaxis by medication use in the district Pharmacovigilance program of Bogotá D.C. 2009-2018 it can be concluded that the female sex reported a greater number of cases.

LEER
Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable
...
Martínez Cardozo, Luz Adriana | 2019

The ductus arteriosus is a vascular structure that connects the proximal descending aorta with the main pulmonary artery near the origin of the pulmonary branch, (Ruiz, D; et al. 2008) and that results in a pulmonary diversion during fetal life. This duct must be closed for a maximum of 3 days in full-term newborns (RNT), but in certain cases this closure does not occur naturally, this is called as Permeable Arterial Conduit (CAP) CIE-10 Q250, and must originate its closure pharmacologically or surgically. Currently, Diclofenac and Acetaminophen are used in the treatment of Permeable Arterial Duct Closure, however, there is no record that has the approved indication for use in this pathology, therefore this is considered a Use Not Indicated in the Sanitary Registry (UNIRS). Because there is currently no study on the use of Diclofenac in the treatment of CAP, this work was developed in order to generate a study of use type indication - prescription of Diclofenac, to provide information about the conditions of use of this medication and its safety profile. When characterizing the use of Diclofenac in patients aged 0 to 1 in Colombia during the period from 2014 to 2017, a total of 208 reported cases were found of patients diagnosed with CAP whose pharmacological treatment was Diclofenac, where 107 cases they belong to the female sex and 101 correspond to male patients; These cases were presented mostly in the city of Bogotá D.C., with a total of 88 cases reported. At the same time, when comparing the safety profile of Diclofenac and Acetaminophen, it was found that Acetaminophen has a lower percentage of adverse reactions; therefore, it has a better safety profile. Thanks to this last deduction, the UNIRS form for Acetaminophen was made, evaluating different characteristics such as efficacy, safety, pharmacokinetics, benefits and risks of using this medication as a therapy for the treatment of patent ductus arteriosus duct closure

LEER

‹›

Browsing by Subject "Medicamentos - Efectos secundarios"

Alteraciones en el sitio de administración reportadas por la aplicación intramuscular de medicamentos en Bogotá D. C. 2008-2017 ﻿

Caracterizacióbn de reacciones adversas con Trastuzumab reportadas en Bogotá D. C. 2008-2017 ﻿

Caracterización de efectos adversos a medicamentos asociados a trastornos hematológicos anemia, neutropenia y leucopenia reportados al Programa Distrital de Farmacovigilancia Bogotá D. C. 2012-2016 ﻿

Caracterización de eventos adversos a medicamentos asociados al Whoart alteraciones fetales reportados al programa distrital de farmacovigilancia durante el periodo 2012 a 2017 ﻿

Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016) ﻿

Caracterización de eventos adversos e intoxicaciones reportadas por dipirona al programa distrital de farmacovigilancia Bogotá D.C 2008 - 2012 ﻿

Caracterización de eventos adversos y problemas relacionados con metoclopramida reportados al Programa Distrital de Farmacovigilancia en bogotá D. C. 2008-2017 ﻿

Caracterización de eventos adversos y problemas relacionados con Rivaroxaban reportadas al prorama Mundial de Farmacovigilacia 2006-2018 ﻿

Caracterización de eventos adversos y problemas relacionados con toxina botulinica reportados al programa Distrital de Farmacovigilancia en Bogotá D. C. 2012-2017 ﻿

Caracterización de las reacciones adversas por Gabapentina reportados en Colombia 2008-2016 ﻿

Caracterización de los eventos adversos presentados por Bupivacaína reportados en la ciudad de Bogotá entre 2015-2018 ﻿

Caracterización de reacciones adversas con naloxona Reportados en el programa mundial de farmacovigilancia de la organización mundial de salud (oms) 1974 -20181 ﻿

Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018 ﻿

Caracterización de reportes de reacciones adversas psiquiátricas y problemas relacionados con el uso de Risperidona al Programa Distrital de Farmacovigilancia de Bogotá D. C. 2012-2016 ﻿

Estudio comparativo de reacciones adversas sospechosas con fármacos inhibidores de la bomba de protones reportados al programa Mundial de farmacovigilancia de 1984 a 2017 ﻿

Estudio de casos de alteraciones auditivas y vestibulares con fármacos reportados en Bogotá D. C. 2008-2018 ﻿

Estudio de casos de eventos adversos y problemas relacionados con Denosumab reportados en Bogotá D. C. 2012-2017 ﻿

Estudio de casos de eventos adversos y problemas relacionados con Pegfilgastrim reportados en Bogotá D. C. (2012-2017) ﻿

Estudio de casos de reacciones anafilácticas por administración de medicamentos reportados en la ciudad de Bogotá D. C. entre los años 2009-2018 ﻿

Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable ﻿

Envíos recientes

Alteraciones en el sitio de administración reportadas por la aplicación intramuscular de medicamentos en Bogotá D. C. 2008-2017

Caracterizacióbn de reacciones adversas con Trastuzumab reportadas en Bogotá D. C. 2008-2017

Caracterización de efectos adversos a medicamentos asociados a trastornos hematológicos anemia, neutropenia y leucopenia reportados al Programa Distrital de Farmacovigilancia Bogotá D. C. 2012-2016

Caracterización de eventos adversos a medicamentos asociados al Whoart alteraciones fetales reportados al programa distrital de farmacovigilancia durante el periodo 2012 a 2017

Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016)

Caracterización de eventos adversos e intoxicaciones reportadas por dipirona al programa distrital de farmacovigilancia Bogotá D.C 2008 - 2012

Caracterización de eventos adversos y problemas relacionados con metoclopramida reportados al Programa Distrital de Farmacovigilancia en bogotá D. C. 2008-2017

Caracterización de eventos adversos y problemas relacionados con Rivaroxaban reportadas al prorama Mundial de Farmacovigilacia 2006-2018

Caracterización de eventos adversos y problemas relacionados con toxina botulinica reportados al programa Distrital de Farmacovigilancia en Bogotá D. C. 2012-2017

Caracterización de las reacciones adversas por Gabapentina reportados en Colombia 2008-2016

Caracterización de los eventos adversos presentados por Bupivacaína reportados en la ciudad de Bogotá entre 2015-2018

Caracterización de reacciones adversas con naloxona Reportados en el programa mundial de farmacovigilancia de la organización mundial de salud (oms) 1974 -20181

Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018

Caracterización de reportes de reacciones adversas psiquiátricas y problemas relacionados con el uso de Risperidona al Programa Distrital de Farmacovigilancia de Bogotá D. C. 2012-2016

Estudio comparativo de reacciones adversas sospechosas con fármacos inhibidores de la bomba de protones reportados al programa Mundial de farmacovigilancia de 1984 a 2017

Estudio de casos de alteraciones auditivas y vestibulares con fármacos reportados en Bogotá D. C. 2008-2018

Estudio de casos de eventos adversos y problemas relacionados con Denosumab reportados en Bogotá D. C. 2012-2017

Estudio de casos de eventos adversos y problemas relacionados con Pegfilgastrim reportados en Bogotá D. C. (2012-2017)

Estudio de casos de reacciones anafilácticas por administración de medicamentos reportados en la ciudad de Bogotá D. C. entre los años 2009-2018

Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable

Alteraciones en el sitio de administración reportadas por la aplicación intramuscular de medicamentos en Bogotá D. C. 2008-2017

Caracterizacióbn de reacciones adversas con Trastuzumab reportadas en Bogotá D. C. 2008-2017

Caracterización de efectos adversos a medicamentos asociados a trastornos hematológicos anemia, neutropenia y leucopenia reportados al Programa Distrital de Farmacovigilancia Bogotá D. C. 2012-2016

Caracterización de eventos adversos a medicamentos asociados al Whoart alteraciones fetales reportados al programa distrital de farmacovigilancia durante el periodo 2012 a 2017

Caracterización de eventos adversos con medicamentos corticosteroides reportados al Programa Nacional de Farmacovigilancia en Colombia (2005-2016)

Caracterización de eventos adversos e intoxicaciones reportadas por dipirona al programa distrital de farmacovigilancia Bogotá D.C 2008 - 2012

Caracterización de eventos adversos y problemas relacionados con metoclopramida reportados al Programa Distrital de Farmacovigilancia en bogotá D. C. 2008-2017

Caracterización de eventos adversos y problemas relacionados con Rivaroxaban reportadas al prorama Mundial de Farmacovigilacia 2006-2018

Caracterización de eventos adversos y problemas relacionados con toxina botulinica reportados al programa Distrital de Farmacovigilancia en Bogotá D. C. 2012-2017

Caracterización de las reacciones adversas por Gabapentina reportados en Colombia 2008-2016

Caracterización de los eventos adversos presentados por Bupivacaína reportados en la ciudad de Bogotá entre 2015-2018

Caracterización de reacciones adversas con naloxona Reportados en el programa mundial de farmacovigilancia de la organización mundial de salud (oms) 1974 -20181

Caracterización de reacciones adversas de medicamentos derivados de enzimas ocurridas en Bogotá D. C. durante el periodo 2008-2018

Caracterización de reportes de reacciones adversas psiquiátricas y problemas relacionados con el uso de Risperidona al Programa Distrital de Farmacovigilancia de Bogotá D. C. 2012-2016

Estudio comparativo de reacciones adversas sospechosas con fármacos inhibidores de la bomba de protones reportados al programa Mundial de farmacovigilancia de 1984 a 2017

Estudio de casos de alteraciones auditivas y vestibulares con fármacos reportados en Bogotá D. C. 2008-2018

Estudio de casos de eventos adversos y problemas relacionados con Denosumab reportados en Bogotá D. C. 2012-2017

Estudio de casos de eventos adversos y problemas relacionados con Pegfilgastrim reportados en Bogotá D. C. (2012-2017)

Estudio de casos de reacciones anafilácticas por administración de medicamentos reportados en la ciudad de Bogotá D. C. entre los años 2009-2018

Estudio de utilización tipo indicación - prescripción del Diclofenaco en el tratamiento del cierre de conducto arterioso permeable